Clinical Brief: Challenges and Advances in Diabetic Kidney Disease

This enduring clinical brief was developed from a primetime symposium at the 2021 CMHC Annual Congress. Moderated by Dr. Bakris, the symposium highlighted the importance of and the challenges in managing renal disease in patients with diabetes. The panel also gave a thorough background on the development of a non-steroidal mineralocorticoid receptor antagonist, a new drug class that shows promising results in tackling inflammation and fibrosis in patients with diabetes and renal disease.

Target Audience

This activity is designed for US-based healthcare professionals, including primary care clinicians (PCPs), registered nurses, nurse practitioners (NPs), physician assistants (PAs), endocrinologists, diabetologists, pharmacists, cardiologists, lipidologists, dieticians, and other allied health professionals.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Identify T2DM patients at risk for kidney disease or kidney disease progression.
  • Develop appropriate treatment options for patients with DKD based on current guideline recommendations and available treatment options.
  • Summarize the efficacy, safety, and mechanisms of action of emerging treatment options for DKD.
Course summary
Available credit: 
  • 1.00 ABIM MOC and AMA PRA Category 1 Credit
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 ANCC
  • 1.00 CDE
  • 1.00 Participation
Course opens: 
Course expires: 

George L. Bakris, MD (Chair)
Professor of Medicine
Director, ASH Comprehensive Hypertension Center
University of Chicago Medicine
Chicago, IL

Dr. Bakris discloses the following: 

Consultant for: Merck, Bayer, Vifor, Ionis, Alnylam, Astra Zeneca, Horizon, Bayer, Novo Nordisk
Employee of: University of Chicago Medicine


Rajiv Agarwal, MD, MS
Professor of Medicine
Indiana University School of Medicine and VA Medical Center
Indianapolis, IN

Dr. Agarwal discloses the following: 

Consultant for: Akebia, Bayer, Boehringer, Relypsa, Reata, Diamedica, and Merck.


Bertram Pitt, MD
Professor of Medicine, Emeritus
University of Michigan School of Medicine
Ann Arbor, MI

Dr. Pitt discloses the following: 

Consulting Fees: Bayer, AstraZeneca, Sanofi/Lexicon, Boehringer Ingelheim/Lilly, Vifor, SCPharmaceuticals, SQinnovations, G3 Pharmaceuticals, Sarfez, Tricida, KBP biosciences, Cereno scientific, Phasebio, Protonintel, Brainstorm medical
Stock options less than 5%: Vifor, SCPharmaceuticals, SQinnovations, G3Pharmaceuticals, Sarfez, KBP biosciences, Cereno scientific, Protonintel, Brainstorm medical, Tricida
Patents: US Patent 99314 12-site specific delivery of eplerenone to the myocardium, US patent pending
Agents: 63/054, 783 Histone -acetylation -modulating agents for the treatment and prevention of organ injury

1 hour

Supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.


In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Tarsus Cardio Inc. dba Cardiometabolic Health Congress (CMHC). Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours. 

Postgraduate Institute for Medicine designates this continuing education activity for 1.0contact hour(s) (.10 CEUs) of the Accreditation Council for Pharmacy Education.

This is an application-based activity. Universal Activity Numbers (UAN): JA4008162-9999-22-288-H01-P

For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.

This program offers 1.0 CPEUs for dieticians.


Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) maintenance of certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The PIM planners and others have nothing to disclose. The CMHC planners and others have nothing to disclose.

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA.  The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management.  Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

During the period June 1, 2022 through June 1, 2023, participants must read the learning objectives and faculty disclosures, study the educational activity, obtain a score of 75% or better on the post-test, and complete the evaluation. Upon completing, your certificate will be available for print. For questions about receiving certificates, please contact us at

For questions about the accreditation of this activity, please visit

For Pharmacists: Please complete the evaluation instructions above. Upon registering and completing the activity evaluation, your transcript information will be sent to the NABP CPE Monitor Service within 4-6 weeks.

Available Credit

  • 1.00 ABIM MOC and AMA PRA Category 1 Credit
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 ANCC
  • 1.00 CDE
  • 1.00 Participation
Please login or register to take this course.

Required Hardware/software

A computer with an internet connection

Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser

Other additional software may be required such as PowerPoint or Adobe Acrobat Reader.